Literature DB >> 22380593

Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.

L K Petersen1, Y Phanse, A E Ramer-Tait, M J Wannemuehler, B Narasimhan.   

Abstract

Advancements toward an improved vaccine against Bacillus anthracis, the causative agent of anthrax, have focused on formulations composed of the protective antigen (PA) adsorbed to aluminum hydroxide. However, due to the labile nature of PA, antigen stability is a primary concern for vaccine development. Thus, there is a need for a delivery system capable of preserving the immunogenicity of PA through all the steps of vaccine fabrication, storage, and administration. In this work, we demonstrate that biodegradable amphiphilic polyanhydride nanoparticles, which have previously been shown to provide controlled antigen delivery, antigen stability, immune modulation, and protection in a single dose against a pathogenic challenge, can stabilize and release functional PA. These nanoparticles demonstrated polymer hydrophobicity-dependent preservation of the biological function of PA upon encapsulation, storage (over extended times and elevated temperatures), and release. Specifically, fabrication of amphiphilic polyanhydride nanoparticles composed of 1,6-bis(p-carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane best preserved PA functionality. These studies demonstrate the versatility and superiority of amphiphilic nanoparticles as vaccine delivery vehicles suitable for long-term storage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22380593      PMCID: PMC3325798          DOI: 10.1021/mp2004059

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  39 in total

Review 1.  Localization dose and time of antigens determine immune reactivity.

Authors:  R M Zinkernagel
Journal:  Semin Immunol       Date:  2000-06       Impact factor: 11.130

Review 2.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Protein stability in the presence of polymer degradation products: consequences for controlled release formulations.

Authors:  Amy S Determan; Jennifer H Wilson; Matt J Kipper; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Biomaterials       Date:  2006-02-28       Impact factor: 12.479

4.  Microphase separation in bioerodible copolymers for drug delivery.

Authors:  E Shen; R Pizsczek; B Dziadul; B Narasimhan
Journal:  Biomaterials       Date:  2001-02       Impact factor: 12.479

5.  Anthrax vaccine powder formulations for nasal mucosal delivery.

Authors:  Ge Jiang; Sangeeta B Joshi; Laura J Peek; Duane T Brandau; Juan Huang; Matthew S Ferriter; Wendy D Woodley; Brandi M Ford; Kevin D Mar; John A Mikszta; C Robin Hwang; Robert Ulrich; Noel G Harvey; C Russell Middaugh; Vincent J Sullivan
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

6.  Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens.

Authors:  Brenda Carrillo-Conde; Elise Schiltz; Jing Yu; F Chris Minion; Gregory J Phillips; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2010-02-01       Impact factor: 8.947

7.  Synthesis of novel biodegradable polyanhydrides containing aromatic and glycol functionality for tailoring of hydrophilicity in controlled drug delivery devices.

Authors:  Brandon M Vogel; Surya K Mallapragada
Journal:  Biomaterials       Date:  2005-03       Impact factor: 12.479

8.  High throughput cell-based screening of biodegradable polyanhydride libraries.

Authors:  Andrew F Adler; Latrisha K Petersen; Jennifer H Wilson; Maria P Torres; Jon B Thorstenson; Stuart W Gardner; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Comb Chem High Throughput Screen       Date:  2009-08-01       Impact factor: 1.339

Review 9.  Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.

Authors:  Jean-Nicolas Tournier; Robert G Ulrich; Anne Quesnel-Hellmann; Mansour Mohamadzadeh; Bradley G Stiles
Journal:  Expert Rev Anti Infect Ther       Date:  2009-03       Impact factor: 5.091

10.  Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Authors:  Bret D Ulery; Devender Kumar; Amanda E Ramer-Tait; Dennis W Metzger; Michael J Wannemuehler; Balaji Narasimhan
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

View more
  25 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

Authors:  J E Vela Ramirez; R Roychoudhury; H H Habte; M W Cho; N L B Pohl; B Narasimhan
Journal:  J Biomater Sci Polym Ed       Date:  2014-07-28       Impact factor: 3.517

3.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

4.  Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.

Authors:  Julia E Vela-Ramirez; Jonathan T Goodman; Paola M Boggiatto; Rajarshi Roychoudhury; Nicola L B Pohl; Jesse M Hostetter; Michael J Wannemuehler; Balaji Narasimhan
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

5.  Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles.

Authors:  Vijaya B Joshi; Sean M Geary; Brenda R Carrillo-Conde; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2012-11-12       Impact factor: 8.947

6.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

7.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

8.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422

9.  Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Authors:  Luman Liu; Prakash Kshirsagar; John Christiansen; Shailendra K Gautam; Abhijit Aithal; Mansi Gulati; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Maneesh Jain; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2020-08-25       Impact factor: 4.396

Review 10.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.